Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12852594 | 0.87 | HTT (0.44) | HTTSMN1; SMN2ALDH1A1LIMK2NPC1 | |
| SCHEMBL20888440 | 0.87 | NPY5R (0.41) | ALDH1A1KMT2A | |
| SCHEMBL20888459 | 0.85 | HTT (0.44) | HTTNPC1MEN1KMT2ATDP1 | |
| SCHEMBL22318570 | 0.78 | CA12 (0.50) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL20888443 | 0.77 | ALDH1A1 (0.44) | HTTSMN1; SMN2ALDH1A1NPC1MAPT | |
| SCHEMBL20888486 | 0.77 | ACACB (0.46) | HTTSMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL13412201 | 0.77 | CES2 (0.53) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL1196746 | 0.77 | KMT2A (0.39) | HTTMEN1KMT2ATDP1HSD17B10 | |
| SCHEMBL18175980 | 0.77 | PBRM1 (0.49) | SMN1; SMN2ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL394512 | 0.75 | HSD11B1 (0.53) | SMN1; SMN2ALDH1A1LIMK2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11590118-B2 | Methods and compositions for treating retina-associated disease using CCR3-inhibitors | ALKAHEST INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11382907-B2 | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors | ALKAHEST, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210106577-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20190105314-A1 | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors | ALKAHEST, INC. | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105314-A1 | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | HTT 18/4885SMN1; SMN2 7/4885ALDH1A1 4663/4885 |
| US-20210106577-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | HTT 3717/4885SMN1; SMN2 527/4885ALDH1A1 3361/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | HTT 3717/4885SMN1; SMN2 527/4885ALDH1A1 3361/4885 |
| US-11590118-B2 | Methods and compositions for treating retina-associated disease using CCR3-inhibitors | CCR3, CCR1, CCR4 | HTT 3717/4885SMN1; SMN2 527/4885ALDH1A1 3361/4885 |
| US-11382907-B2 | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors | CCR3, CCR1, CCR4 | HTT 18/4885SMN1; SMN2 7/4885ALDH1A1 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.